1Klasterky J, Sculier JP. Non surgical combined modality therapies in non-small-cell lung cancer[J] .Chest, 1986, 89(Suppl): 289s-294s. 被引量：1
2Kunitoh H, Watanabe K, Onoshi T, et al. Phase Ⅱ trial of Docetaxel in previously untreated advanced non - small - cell lung cancer[J] .J Clin Oncol, 1996,14(5) : 1649-1655. 被引量：1
3Zalcberg J, Millward M,Bishop J, et al. Phase Ⅱ study of Docetaxel and Cisplatin in advanced non-small-cell lung cancer[J] .J Clin Oncol,1998,16(5) : 1948-1953. 被引量：1
4Miller VA, Rigas JR,Francis PA, et al. Phase Ⅱ trial of 75 mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small-cell lung cancer[J]. Cancer, 1995,75(4) :968-972. 被引量：1
5Fossella F,Pereira JR,Von Pawel J,et al.Randomized,multinational,phase Ⅲ study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer:the TAX 326 study group[J].J Clin Oncol,2003,21(16):3016-3024. 被引量：1
6Le Chevalier T,Berille J, Zalcberg JR,et al.Overview of docetaxel(Taxotere)/cisplatin combination in non-small cell lung cancer[J].Semin Oncol,1999,26(3 Suppl 11):13-18. 被引量：1
7Kubota K,Watanabe K,Kunitoh H,et al.Phase Ⅲ randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage Ⅳ non-small cell lung cancer:the Japanese Taxotere Lung Cancer Study Group[J].J Clin Oncol,2004,15:22(2):254-261. 被引量：1
8Marrogi AJ,Travis WD,Welsh JA,et al.Nitric oxide synthase,cyclooxygenase 2,and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma[J].Clin Cancer Res,2000,6(12):4739-4744. 被引量：1
9Dannenberg AJ,Altorki NK,Boyle JO,et al.Cyclo-oxygenase 2:a pharmacological target for the prevention of cancer[J].Lancet Oncol,2001,2(9):544-551. 被引量：1
10Altorki NK,Keresztes RS,Port JL,et al.Celecoxib,a selective cyclo-oxygenase-2 inhibitor,enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small cell lung cancer[J].J Clin Oncol,2003,21(14),2645-2650. 被引量：1
4Hesketh PJ, Lilenbanm RC, Chansky K, et al. Chemotherapy in patients ≥80 with advanced non-small cell lung cancer: com- bined results from SWOG 0027 and LUN 6 [ J ]. J Thorac Oncol, 2007, 2:494-498. 被引量：1
5Tokujiro Y, Affiliations Koji Y, Riichiroh M, et al. Feasibility study of postoperative adjuvant chemotherapy with S-1 ( tegaful, gimeracil, oteracil potassium)for non-small cell lung cancer LOGIK 0601 study[J]. Lung Cance, 2010, 32:184-187. 被引量：1
7MAIONE P,COMUNAIE D.Adjuvant chemotherapy in elde-rly patients with non-small-cell lung cancer. CancerControl . 2007 被引量：1
8E Bria,F Cuppone,M Ciccarese.Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. Cancer Treatment Reviews . 2006 被引量：1
9Schiller JH,Harrington D,Belani CP,et al.Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New England Journal of Homeopathy . 2002 被引量：1
10Hainsworth JD,Spigel DR,Farley C, et al. Weekly docetaxel ver- sus docetaxel/gemeitabine in the treatment of elderly or poor per- formance status patients with advnced non-small cell lung caneer: a randomized phase 3 trial of the Minnie Pearl Cancer Researeh Network[J]. Cancer, 2007,110(9) : 2027-2034. 被引量：1
